Key result
In a real-world STEMI population undergoing primary PCI, bivalirudin use resulted in 5.2% mortality and 7.5% MACE at 30 days, with no significant difference compared to heparin/GPI.
Why the study?
Does bivalirudin improve 30-day outcomes compared to heparin/GPI in patients undergoing primary PCI for STEMI?
Population
968 consecutive STEMI patients undergoing primary percutaneous coronary intervention
Comparison
Bivalirudin administered as a bolus, high-dose… vs Heparin/glycoprotein IIb/IIIa receptor inhibition
Design
Cohort
Follow-up
30 days
Authors
Loading...
Supports similar outcomes with bivalirudin in real-world STEMI PCI; leaves open need for randomized confirmation.
Cohort (n=968)
Does bivalirudin improve 30-day outcomes compared to heparin/GPI in patients undergoing primary PCI for STEMI?
Routine use of bivalirudin with a post-PCI low-dose infusion in a real-world primary PCI population for STEMI is associated with good 30-day outcomes and infrequent acute stent thrombosis, comparable to heparin/GPI.
Shelton et al. (2013) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=968). Bivalirudin vs. Heparin/GPI (abciximab) was evaluated on Mortality, major adverse cardiovascular events (MACE), major bleeding and stent thrombosis at 30 days. In a real-world STEMI population undergoing primary PCI, bivalirudin use resulted in 5.2% mortality and 7.5% MACE at 30 days, with no significant difference compared to heparin/GPI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: